Case Report

Non RhD isoimmunization causing severe hemolytic disease of fetus and newborn in Rh positive pregnancies: report of 2 cases with review of literature

Geetika Sharma, Sangeeta Pahuja*, Deeksha Singh, Ramvilash, Manisha

INTRODUCTION

Hemolytic Disease of Fetus and Newborn (HDFN) is the destruction of fetal and newborn red cells by maternal red cell alloantibodies that are specific for inherited paternal red cell alloantigen(s). A French midwife in a set of twins first reported it in 1609. In 1941, Levine and colleagues suggested that destruction of red cells (RBCs) in the fetus and newborn may be due to maternal alloimmunization against blood group antigens of the unborn child.1,2 HDFN is one of the major causes of perinatal morbidity and mortality in India. The antibodies most commonly associated with severe HDFN are anti-D, anti-c and anti-K (KEL1).3 Anti D immunoprophylaxis has led to dramatic reduction in the rates of alloimmunization due to anti D from 14% to 1-2% in west, which was further reduced significantly by antenatal immunoprophylaxis to 0.1%.4 Apart from immunoprophylaxis, more widespread antenatal antibody screening has contributed to the decline in rate of morbidity and mortality by anti D alloimmunization. Other factors like advancements in fetal assessment by Doppler (Middle Cerebral Artery Peak Systolic Velocity), ultrasonography, cordocentesis, allele-specific gene amplification studies on fetal cells in amniotic fluid, fetal DNA analysis in maternal plasma have significantly contributed in decreased fetal mortality. In India, though anti D is still the most common antibody responsible for alloimmunization, but the advancements in the screening techniques have changed dramatically the spectrum of antibodies causing alloimmunization in antenatal women over the last few decades.

HDFN is one of the major causes of perinatal morbidity and mortality in India. The antibodies most commonly associated with severe HDFN are anti-D, anti-c and anti-K (KEL1).3 Anti D immunoprophylaxis has led to dramatic reduction in the rates of alloimmunization due to anti D from 14% to 1-2% in west, which was further reduced significantly by antenatal immunoprophylaxis to 0.1%.4

ABSTRACT

Anti D immunoprophylaxis widespread use in antenatal patients has led to dramatic reduction in the rates of alloimmunization due to anti D, which is the most common Rh antibody causing severe Hemolytic Disease of Fetus and Newborn (HDFN). However, there has been increase in the rates of non Rh D antibodies causing alloimmunization in pregnant women and leading to moderate to severe HDFN. We hereby report two cases of neonates presenting with moderate to severe HDFN with strongly positive DAT due to Rh anti-c antibody in Rh positive mothers. Thus, antenatal antibody screening should be done in all Rh-positive pregnant women to prevent the diagnostic delay of HDFN occurring due to Non anti-D isoimmunization in the fetus.

Keywords: Anti-c antibody, Hemolytic disease, Hyperbilirubinemia, Isoimmunization

Received: 19 January 2020
Revised: 23 February 2020
Accepted: 27 February 2020

*Correspondence:
Dr. Sangeeta Pahuja,
E-mail: sangeeta.sindhwani@gmail.com
CASE REPORT

We hereby report 2 cases of non Rh (D) isoimmunization in neonates from our tertiary care hospital presenting with HDFN.

Case 1

A term female infant, appropriate for gestational age with birth weight of 3 Kg presented in the emergency of Kalawati Saran Children’s hospital on day 5 of life with complaints of lethargy, decreased oral intake, yellowish discoloration of sclera and skin (involving the palms and soles). It was progressively increasing since 2nd day of life. The baby was delivered by caesarean section in outside hospital and it was an unbooked and unimmunized pregnancy, G2 P2 L0A1 with history of intrauterine death of first female child at term. The general condition of the patient was poor. Baby presented with tachycardia (HR - 138/min) and Tachypnea (RR-62/min). On physical examination, icterus was present along with mild pallor. However, no hepatosplenomegaly was evident. No history of blood transfusion during previous/present pregnancy was elicited.

Hematological findings of the baby revealed mild anemia Hb- 12.5g/dL, RBC count- 3.07x10^6/μL and raised reticulocyte count (15%). Biochemical investigation showed markedly raised indirect bilirubin (Total bilirubin-40.2 mg/dL, indirect bilirubin- 21.0 mg/dL). Clinically, neonatal sepsis was considered, and double surface phototherapy was started. However, as the child did not show improvement, meanwhile double volume exchange transfusion was planned and requisition for the same was received in the Department of Immunohematology and Blood Transfusion in our hospital.

On physical examination, icterus and severe pallor was present. (Hb-3 g/dL, hematocrit-9) with raised reticulocyte count (corrected R/C-5%). Biochemical investigation showed indirect hyperbilirubinemia (Total bilirubin-12mg/dL, indirect bilirubin- 9mg/dL). Top up transfusion was planned for the baby in view of severe anemia and requisition for the same was received in the Department of Immunohematology and Blood Transfusion in our hospital.

In case 1, mother’s and baby blood group were ‘O’ Rh positive (Figure 1). Father’s sample was not available. Antibody screening 3-cell panel (ID- Diacell 1-11-111 asia, Biorad) of the mother sample was positive. Further, antibody identification 11-cell panel (ID-Diapanel) revealed presence of anti c alloantibody by ruling out other clinically significant antibodies.

Case 2

A term female infant presented on day 6 of life in the emergency of Kalawati Saran Children’s hospital with complaints of yellowish discoloration of the sclera and lethargy. The baby was delivered in an outside hospital and it was an unbooked and unimmunized pregnancy, G2 P2 L1A0 with no bad obstetric history. On physical examination, icterus and severe pallor was present. (Hb-3 g/dL, hematocrit-9) with raised reticulocyte count (corrected R/C-5%). Biochemical investigation showed indirect hyperbilirubinemia (Total bilirubin-12mg/dL, indirect bilirubin- 9mg/dL). Top up transfusion was planned for the baby in view of severe anemia and requisition for the same was received in the Department of Immunohematology and Blood Transfusion in our hospital.

In case 1, mother’s and baby blood group were ‘O’ Rh positive (Figure 1). Father’s sample was not available. Antibody screening 3-cell panel (ID- Diacell 1-11-111 asia, Biorad) of the mother sample was positive. Further, antibody identification 11-cell panel (ID-Diapanel) revealed presence of anti c alloantibody by ruling out other clinically significant antibodies.
strongly positive (4+) and further DCT profile showed presence of IgG. Rh- kell antigen phenotyping revealed that mother was ‘c’ antigen negative, father was ‘c’ antigen positive and baby was ‘c’ antigen positive. (Figure 6) This further supported and confirmed our findings.

Thus, it was allo anti c antibody in the mother, which was causing moderate and severe HDFN in both the neonates. Elution studies of the baby sample could not be done in both the cases, as the sample was insufficient. Blood unit O Rh positive (R1R1), negative for c antigen was put up for AHG crossmatch and was issued for exchange transfusion in case 1 and for top up transfusion in case 2 with close follow up of the baby.

DISCUSSION

Antenatal services in India are fragmented and not uniform hence there is limited published data on alloimmunization rates among pregnant women in India.

Screening for alloantibodies in antenatal patients is being done primarily for Rh D negative women or patients presenting with bad obstetric history due to which many clinically significant alloantibodies are missed in Rh D positive pregnant females causing HDFN in the baby. This fact is clearly highlighted in both our cases as both the mothers were Rh positive and the neonates presented in our hospital emergency after delay of 4 or 5 days of life with markedly raised levels of serum bilirubin. Though HDFN is a preventable morbidity in neonates, but with such high levels of serum bilirubin the child had already developed bilirubin encephalopathy and the consequences caused by it are irreversible. The crucial time was wasted in antibody identification and crossmatch to search for a compatible blood unit for the baby. Moreover, antibody-screening techniques are not well developed in many centers. As a result the
specificity of offending antibody could not be determined and they perform random cross match with O Rh negative blood unit presuming the offending antibody to be anti D. This leads to further delay in transfusion of compatible blood unit to the baby presenting with severe anemia as generally the O Rh negative blood units put up for crossmatch are incompatible with the baby sample. Many non-RhD alloantibodies are identified when neonate develops jaundice.

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>No. of pregnant patients</th>
<th>Anti c Antibody prevalence</th>
<th>Pregnancy outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrup J et al⁹</td>
<td>1977</td>
<td>63 antenatal patients with anti c</td>
<td>63 -pregnant women. In 42 cases- baby was c antigen positive, c antigen negative babies were excluded.</td>
<td>10 neonates- unaffected 30 neonates- DAT +ve- mild HDFN 2 neonates- Severe HDFN</td>
</tr>
<tr>
<td>Hardy J et al¹⁰</td>
<td>1981</td>
<td>3,80,790 pregnant females screened. In 733 antenatal cases- Rh positive ICT +</td>
<td>Grp 1: anti c, anti E, anti c+E, anti C, anti e= 517 patients Grp 2: non Rh antibodies=136 patients Grp 3: Rh + non Rh Ab= 26 patients (c+others=13) Anti c= 139/733(19%) Anti c+E=60/733(8.2%) Anti c + others systems=13/733(1.8%)</td>
<td>Infants of anti c Rh +ve mothers= 166 27/166(19.4%) – needed transfusion support 3/166(2.2%)- Death from HDFN Infants of anti c+E Rh +ve mothers= 87 12/87 (17.4%) transfusion support 2/87(3%)- Death from HDFN In grp 3 all infants needed transfusion support.</td>
</tr>
<tr>
<td>Bowell PJ et al¹¹</td>
<td>1986</td>
<td>2,80,000 Pregnant women</td>
<td>177/280000(0.06%)-anti c 91- only anti c 67 - anti c+anti-E 19 - anti c+ one or more of the following: anti-C⁸, Lea, Leb, Jka,Jkb, s, Kell, Kp⁹</td>
<td>2- Severe HDFN 11- DVET 1-Mortality Rest- unaffected</td>
</tr>
<tr>
<td>Koelewijn J et al¹²</td>
<td>2000</td>
<td>3,05,000 antenatal women 1002 antenatal women (antibody screen +)</td>
<td>152/1002 anti c [93- only anti c 47- c+E 12- c + other than anti-D, -K, or –E]</td>
<td>146/152- at risk for HDFN (father +ve for the antigen) 118/152= infant c antigen +ve Severe HDFN in 12 cases/118(10.2%) [10- only antic l- anti c +Ec+E l- anti c+ other non Rh]</td>
</tr>
<tr>
<td>Hackney DN et al¹³</td>
<td>2004</td>
<td>102 pregnant women with anti c 55- complete details</td>
<td>55</td>
<td>46/55(84%)- DAT +ve 12/46 (26%)- Severe HDFN</td>
</tr>
<tr>
<td>Thakral B et al¹⁴</td>
<td>2007</td>
<td>01</td>
<td>NA</td>
<td>Moderate HDFN</td>
</tr>
<tr>
<td>Singla S et al¹⁵</td>
<td>2010</td>
<td>01</td>
<td>NA</td>
<td>Severe HDFN DVET</td>
</tr>
<tr>
<td>Murki et al¹⁶</td>
<td>2012</td>
<td>02</td>
<td>NA</td>
<td>Moderate HDFN (1- DVET (2- Phototherapy)</td>
</tr>
<tr>
<td>Sheeladevi CS et al¹⁷</td>
<td>2013</td>
<td>01</td>
<td>NA</td>
<td>Severe HDFN fetal hydrops</td>
</tr>
<tr>
<td>Pandu Rao et al¹⁸</td>
<td>2015</td>
<td>01</td>
<td>NA</td>
<td>Severe HDFN DVET</td>
</tr>
<tr>
<td>Shyam Sunder Mina et al¹⁹</td>
<td>2017</td>
<td>01</td>
<td>NA</td>
<td>Moderate HDFN</td>
</tr>
<tr>
<td>Present case</td>
<td>2018</td>
<td>2 cases anti c antibody +</td>
<td>NA</td>
<td>1- Severe HDFN 2- Moderate HDFN</td>
</tr>
</tbody>
</table>

(NA: Not Applicable)
All antibodies to Rh-system antigens are considered capable of causing severe HDFN though anti-c is clinically the most important Rh antigen after anti-D and often causes severe HDFN, moderate HDFN can be caused by anti-Cw and anti-Cx whereas anti-C, -E, and -e rarely cause mild HDFN.\textsuperscript{2,3,5} Phenotypic frequency of ‘c’ antigen and its potency is responsible for emerging anti-c alloimmunization.

Alloimmunization in pregnant women varies from 0.4% to 2.7% worldwide. Very few studies are available from India subcontinent on prevalence and significance of alloantibodies in pregnancy. Alloimmunization rates in the Rh(D) antigen negative and Rh(D)antigen positive groups was 10.7% versus 0.12% respectively in a prospective study done in 3577 multigravida women by Pahuja et al in 2011 at our RBTC, out of which alloimmunization due to anti-c antibody was seen in 1.96% cases. Lurie et al and Adenijii et al reported alloimmunization rates among Rh positive women 0.2% and 0.15% respectively.\textsuperscript{5-8}

Majority of these studies are mainly from urban hospitals/tertiary care centers. Hence exact magnitude of problem in rural India is not known. Globally with universal anti D Immunoprophylaxis non-D antibodies contribute to major chunk of alloimmunization in pregnancy. Also, there is paucity of literature on the studies emphasizing the role of Non RhD isoimmunization especially anti c antibody isoimmunization in Rh positive antenatal patients, monitoring of such pregnancies, degree of HDN in the fetus, its outcome and its management. Few studies in the past have highlighted anti c isoimmunization in Rh D positive pregnancies and reported the prevalence and outcome of pregnancies complicated by anti c alloimmunization (Table 1).

The first case of anti-c isoimmunization was reported in 1944, while the first case of HDN due to anti-c antibodies in Rh-D positive mother in India was published in a retrospective diagnosis made in 2007.\textsuperscript{14,20} In fast growing economy of India it is very unfortunate that we have neonate morbidity and mortality due to HDFN. Though anti D Alloimmunization is prevalent, other non-D alloantibodies are manageable by repeated MCA-PSV and intrauterine transfusion with antigen negative blood unit. If anti c antibody is identified during antenatal screening of the pregnant female the follow up and management of these antenatal pregnant women with anti c alloimmunization is not currently defined, however, studies in the past have suggested that it is similar to that for individuals who harbor anti-D antibodies and suggested critical antibody titer of 1:32 while Bowell PJ et al suggested that pregnancies with titer<16 should be continued till term.\textsuperscript{11,21}

**CONCLUSION**

In majority of transfusion and antenatal care centers in India and other developing countries; routine antenatal antibody screening is done only for Rh-D negative mothers to screen for anti-D antibodies. Universal screening of all antenatal women, including D antigen positive pregnant ones is highly debated and controversial. Antenatal antibody screening should be done in all Rh-positive pregnant women.

The screening guidelines for Rh-D positive females are not clearly defined due to unawareness regarding the potential of these antibodies in causing HDN and perinatal mortality apart from the its cost factor. This results in delay in the diagnosis of HDN due to Non anti-D isoimmunization in the fetus resulting in HDFN.

Severe HDFN caused by antibodies other than anti-D can be treated with intrauterine transfusions (IUTs) during pregnancy and with exchange transfusions after birth.

A close follow-up throughout pregnancy is essential if irregular antibodies are present so that antigen negative compatible blood can be provided in a timely manner for exchange transfusions to reduce the incidence of preventable perinatal mortality and morbidity .The management of anti-c isoimmunization or isoimmunization with any other irregular red cell antibody is similar to the management of anti-D isoimmunised pregnancy with a specification that blood unit used for fetal and/or neonatal transfusion should be negative for that antigen.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** Not Required

**REFERENCES**